

Scott Burwell, PhD



Bio: Scott Burwell, PhD is Founder and CEO of Neurotype Inc. He has 15 years of experience researching Substance Use Disorders (SUDs) using functional brain measurement, including training at the University of Minnesota Center for Twin and Family Research and the Swartz Center for Computational Neuroscience at UC San Diego. Dr. Burwell started Neurotype in 2019 with the aims of improving clinical engagements and outcomes for SUD healthcare; the company is supported by innovation grants from the National Institutes of Health, Minnesota Department of Employment and Economic Development, and Yale University's

Innovation to Impact program. Neurotype is currently building a mobile neurofeedback device that will be used in Opioid Use Disorder (OUD) treatment to detect biomarkers related to cue-induced drug craving, enabling better OUD management and new therapies that engage neurobiology of cravings.

Website: <https://www.neurotype.io>